摘要
目的:探讨乳腺癌组织中E-选择素(E-selectin)及其配体sLe-X(SialylLewis-X)的表达状况及其与肿瘤分化、转移及预后的关系。方法:采用免疫组化技术检测56例乳腺癌及癌旁组织中E-Selectin和sLe-X的表达,分析其表达水平与淋巴转移及临床病理特征之间的关系。20例乳腺纤维瘤标本为对照。结果:E-选择素和sLe-X在乳腺癌组织、癌旁组织、乳腺纤维瘤中阳性表达率分别为82.14%(46/56)、67.86%(38/56)、15.00%(3/20);73.21%(41/56)、58.93%(33/56)、30.00%(6/20)。E-选择素及sLe-X在乳腺癌组织中的表达显著高于癌旁组织及乳腺纤维癌中的表达(P<0.01);有淋巴结转移的乳腺癌组织sLe-X的表达高于无转移组(P<0.01),而E-Selectin在两组间的表达差异无统计学意义(P>0.05)。乳癌组织中E-选择素的表达与ER特征(P=0.001)、肿瘤分期(P=0.026)、肿瘤分化程度(P=0.013)、肿瘤直径(P=0.01)明显相关。单因素分析显示E-选择素表达状态与生存率相关(P=0.027)。结论:E-选择素和SLe-X协同介导了乳腺癌的发生发展及淋巴结转移。E-选择素可能是预测乳腺癌转移和预后的分子标志。
Objective：To investigate the level of E-selectin and its ligand-sLe-X expression in breast carcinoma and its relation with differentiation,metastasis and prognosis.Methods：Immunohistochemistry was used to detect the rate of E-selectin and sLe-X in tumor tissues and adjacent normal tissues in 56 samples of breast cancer.A control group coinsisted of 20 patients with a benign breast tumor.Results：The positive rate of E-selectin and ligand-sLe-X in breast cancer tissues,adjacent normal tissues and benign tissues were 82.14%（46/56）vs 73.21%（41/56）,67.86%（38/56）vs 58.93%（33/56）,and 15.00%（3/20）vs 30.00%（6/20）,respectively.The expression of the E-Seleetin and SLe-X breast cancer tissues was significantly higher than in adjacent normal and benign tissues＇ （P〈0.01） and so was the expression of SLe-X（P〈0.01） but not E-Selectin in the metastasis group（P〉0.05）.The expression of E-selectin in breast cancer was significantly higher in women with oestrogen receptor-negative tumors（P=0.001）,poorly differentiated tumor（P=-0.013）,more advanced tumor node metastasis（TNM） stage（P=0.026） and the diameter of tumors（P=0.O1）.Univariate analysis showed that there may be an association between overexpression of E-selectin and a worse prognosis （P=0.027）.Conclusions：E-Selectin and SLe-X play an collaborate role in the lymph metastasis and carcinogenesis of breast cancer.E-selectin as a potent marker may contribute to diagnosis of metastasis and prognosis for breast cancer patients.It may play an important role in targeting and individualized treatment of breast cancer.
出处
《中国交通医学杂志》
2006年第1期20-22,共3页
Chinese Medical JOurnal of Communications
